Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis
This study is aimed at assessing the efficacy and safety of antivascular endothelial growth factor (anti-VEGF) inhibitors in treating age-related macular degeneration (AMD). PubMed, Embase, and Cochrane library were searched. Weighted mean difference (WMD) and relative risk (RR) with 95% confidence...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/6004047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562390574563328 |
|---|---|
| author | Xiaobei Yin Ting He Shanshan Yang Hui Cui Wenlan Jiang |
| author_facet | Xiaobei Yin Ting He Shanshan Yang Hui Cui Wenlan Jiang |
| author_sort | Xiaobei Yin |
| collection | DOAJ |
| description | This study is aimed at assessing the efficacy and safety of antivascular endothelial growth factor (anti-VEGF) inhibitors in treating age-related macular degeneration (AMD). PubMed, Embase, and Cochrane library were searched. Weighted mean difference (WMD) and relative risk (RR) with 95% confidence interval (CI) were applied to assess outcomes. Eighteen randomized controlled trials involved 8,847 neovascular AMD patients were selected for the meta-analysis. Pegaptanib (WMD: 6.70; P<0.001) and ranibizumab (WMD: 17.80; P<0.001) were associated with greater BCVA changes than control after 1 year. Bevacizumab was linked with less changes in central macular thickness after 1 year compared to control (WMD: -38.50; P<0.001), but more changes compared to ranibizumab (WMD: 10.69; P=0.024). The incidence of gain of 15 or more letter visual acuity after 1 year was increased when compared with bevacizumab versus control (RR: 7.80; P=0.001), pegaptanib versus control (RR: 2.83; P=0.015), and ranibizumab versus control (RR: 3.92; P=0.003). Moreover, ranibizumab was associated with more BCVA changes and an increased incidence of gain of 15 or more letter visual acuity after 2 years compared with control (RR: 5.77; P<0.001). This study found that most anti-VEGF inhibitors provided better efficacy than non-anti-VEGF intervention, and the treatment effectiveness among various anti-VEGF agents was equally effective. |
| format | Article |
| id | doaj-art-2d7241fb9d9d441cb6139c90a1b0d9c8 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-2d7241fb9d9d441cb6139c90a1b0d9c82025-02-03T01:22:46ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/6004047Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysisXiaobei Yin0Ting He1Shanshan Yang2Hui Cui3Wenlan Jiang4Department of OphthalmologyBeijing Puren HospitalDepartment of OphthalmologySenior Department of OphthalmologyDepartment of OphthalmologyThis study is aimed at assessing the efficacy and safety of antivascular endothelial growth factor (anti-VEGF) inhibitors in treating age-related macular degeneration (AMD). PubMed, Embase, and Cochrane library were searched. Weighted mean difference (WMD) and relative risk (RR) with 95% confidence interval (CI) were applied to assess outcomes. Eighteen randomized controlled trials involved 8,847 neovascular AMD patients were selected for the meta-analysis. Pegaptanib (WMD: 6.70; P<0.001) and ranibizumab (WMD: 17.80; P<0.001) were associated with greater BCVA changes than control after 1 year. Bevacizumab was linked with less changes in central macular thickness after 1 year compared to control (WMD: -38.50; P<0.001), but more changes compared to ranibizumab (WMD: 10.69; P=0.024). The incidence of gain of 15 or more letter visual acuity after 1 year was increased when compared with bevacizumab versus control (RR: 7.80; P=0.001), pegaptanib versus control (RR: 2.83; P=0.015), and ranibizumab versus control (RR: 3.92; P=0.003). Moreover, ranibizumab was associated with more BCVA changes and an increased incidence of gain of 15 or more letter visual acuity after 2 years compared with control (RR: 5.77; P<0.001). This study found that most anti-VEGF inhibitors provided better efficacy than non-anti-VEGF intervention, and the treatment effectiveness among various anti-VEGF agents was equally effective.http://dx.doi.org/10.1155/2022/6004047 |
| spellingShingle | Xiaobei Yin Ting He Shanshan Yang Hui Cui Wenlan Jiang Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis Journal of Immunology Research |
| title | Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis |
| title_full | Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis |
| title_fullStr | Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis |
| title_full_unstemmed | Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis |
| title_short | Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis |
| title_sort | efficacy and safety of antivascular endothelial growth factor anti vegf in treating neovascular age related macular degeneration amd a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2022/6004047 |
| work_keys_str_mv | AT xiaobeiyin efficacyandsafetyofantivascularendothelialgrowthfactorantivegfintreatingneovascularagerelatedmaculardegenerationamdasystematicreviewandmetaanalysis AT tinghe efficacyandsafetyofantivascularendothelialgrowthfactorantivegfintreatingneovascularagerelatedmaculardegenerationamdasystematicreviewandmetaanalysis AT shanshanyang efficacyandsafetyofantivascularendothelialgrowthfactorantivegfintreatingneovascularagerelatedmaculardegenerationamdasystematicreviewandmetaanalysis AT huicui efficacyandsafetyofantivascularendothelialgrowthfactorantivegfintreatingneovascularagerelatedmaculardegenerationamdasystematicreviewandmetaanalysis AT wenlanjiang efficacyandsafetyofantivascularendothelialgrowthfactorantivegfintreatingneovascularagerelatedmaculardegenerationamdasystematicreviewandmetaanalysis |